An Expanded Access Programme with Iressa for patients with Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
Study identifier:1839IL/0052
ClinicalTrials.gov identifier:NCT00684385
EudraCT identifier:N/A
CTIS identifier:N/A
Recruitment Complete
Official Title
An International Expanded Access Clinical Programme with ZD1839 (IRESSA) for Patients with Advanced Non-small Cell Lung Cancer(NSCLC) and patients with Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck (H&NC)
Medical condition
Non Small Cell Lung Cancer
Phase
N/A
Healthy volunteers
No
Study drug
ZD1839
Sex
All
Actual Enrollment
265
Study type
Expanded Access
Age
18 Years - 130 Years
Date
Study Start Date: -
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: N/A
Endpoint Classification: None
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Feb 2019 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: ZD1839 250mg administered daily for patients with NSCLC and500mg daily for patients with H&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H&NC will take two tablets at each dose administration. Other Name: Iressa |
Contacts
Investigators
Principal Investigator
Yuri Rukazenkov
AstraZeneca
